To achieve therapeutic levels of the GLP-2 peptide in the chronic setting, prolonged or increased doses of the peptide would be needed, and this is a limitation that is hampering the use of the peptide in the context of IBD treatment in the clinics. Here, GCG is linked to inflammatory bowel disease.